How to Manage COVID-19 in Patients with Diabetes

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.